Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
Departamento Gestión de Conocimiento, Monitoreo y Prospección
Consultas o comentarios: productividad@anid.cl
Consultas o comentarios: productividad@anid.cl
Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trial
| Indexado |
|
||||
| DOI | 10.1093/EHJCVP/PVZ061 | ||||
| Año | 2020 | ||||
| Tipo | artículo de investigación |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
Abstract
Conclusion Although increasing CCI scores are associated with worse outcomes, the efficacy, safety, and net clinical outcomes of edoxaban vs. warfarin were independent of the degree of comorbidity present.
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | Nicolau, Andre M. | Hombre |
Univ Fed Sao Paulo - Brasil
Universidade Federal de São Paulo - Brasil |
| 2 | CORBALAN-HERREROS, RAMON LUIS | Hombre |
Pontificia Universidad Católica de Chile - Chile
Facultad de Medicina - Chile |
| 3 | Nicolau, Jose Carlos | Hombre |
UNIV SAO PAULO - Brasil
Instituto do Coracao do Hospital das Clinicas - Brasil Universidade Federal de São Paulo - Brasil Universidade de São Paulo - Brasil |
| 4 | Ruff, Christian T. | Hombre |
Brigham & Womens Hosp - Estados Unidos
Harvard Med Sch - Estados Unidos Harvard Medical School - Estados Unidos |
| 5 | Zierhut, Wolfgang | Hombre |
Daiichi Sankyo Europe GmbH - Alemania
Daiichi Sankyo Kabushiki-gaisha - Japón Daiichi Sankyo Company, Limited - Japón Daiichi Sankyo Company, Limited - Alemania |
| 6 | Kerschnitzki, Michael | Hombre |
Daiichi Sankyo Europe GmbH - Alemania
Daiichi Sankyo Kabushiki-gaisha - Japón Daiichi Sankyo Company, Limited - Japón Daiichi Sankyo Company, Limited - Alemania |
| 7 | Duris, Tibor | Hombre |
Fak Nemocn Poliklin - República Eslovaca
Fakultná nemocnica s poliklinikou - República Eslovaca |
| 8 | Juul-Moller, Steen | Hombre |
Skane Univ Hosp SUS - Suecia
Skånes universitetssjukhus - Suecia |
| 9 | Voitk, Juri | Hombre |
North Estonia Med Ctr Fdn - Estonia
North Estonia Medical Center - Estonia North Estonia Medical Centre - Estonia |
| 10 | Trevisan, Marco | Hombre |
Karolinska Inst - Suecia
Karolinska Institutet - Suecia |
| 11 | Nordio, Francesco | Hombre |
Brigham & Womens Hosp - Estados Unidos
Harvard Med Sch - Estados Unidos Harvard Medical School - Estados Unidos |
| 12 | Antman, Elliott M. | Hombre |
Brigham & Womens Hosp - Estados Unidos
Harvard Med Sch - Estados Unidos Harvard Medical School - Estados Unidos |
| 13 | Giugliano, Robert P. | Hombre |
Brigham & Womens Hosp - Estados Unidos
Harvard Med Sch - Estados Unidos Harvard Medical School - Estados Unidos |
| Fuente |
|---|
| National Institutes of Health |
| Bristol-Myers Squibb |
| Abbott Laboratories |
| Pfizer |
| AstraZeneca |
| Amgen |
| Boehringer Ingelheim |
| MedImmune |
| Janssen Biotech |
| Medicines Company |
| Daiichi-Sankyo |
| Bayer Corporation |
| Daiichi Sankyo Company |
| Roche |
| Bayer Healthcare |
| Takeda Pharmaceuticals U.S.A. |
| Janssen Pharmaceuticals |
| Daiichi Sankyo Pharma Development |
| Bristol-Myers Squibb Canada |
| Zora Biosciences |
| Bayer Fund |
| Agradecimiento |
|---|
| The ENGAGE AF-TIMI 48 trial was supported by a research grant from Daiichi Sankyo Pharma Development. No funds were provided for preparation of thismanuscript. |
| Conflict of interest: J.C.N. reports receipt of grants/research support from Astrazeneca, Bayer, Bristol-Myers Squibb, CLS Behring, Dalcor, Janssen, Novartis, NovoNordisk, Sanofi, Vifor; receipt of honoraria or consultation fees from Amgen, Bayer, Novartis, Sanofi, Servier: participation in a company sponsored speaker’s bureau Daiichi-Sankyo, Servier. C.T.R. received research grant through institution: Boehringer Ingelheim, Daiichi Sankyo, MedImmune, National Institutes of Health; Honoraria for scientific advisory boards and consulting: Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Janssen, MedImmune, Pfizer, Portola, Anthos. W.Z. and M.K. are employees of Daiichi Sankyo. T.D. and S.J-M. received research grant support from Daiichi Sankyo. E.M.A. received research grant from Daiichi-Sankyo to Brigham and Women’s Hospital for clinical trial with edoxaban. R.P.G. reports Clinical trials/ Research support: Amgen, Daiichi Sankyo. Honoraria for CME Lectures: Amgen, Daiichi Sankyo, Servier. Consultant: Akcea, Amarin, Amgen, Bristol-Myers-Squibb, CVS Caremark, Daiichi Sankyo, Janssen, Lexicon, Pfizer. The TIMI Study Group has received institutional research grant support through Brigham and Women’s Hospital from: Abbott, Amgen, Aralez, AstraZeneca, Bayer HealthCare Pharmaceuticals, Inc., Daiichi-Sankyo, Eisai, GlaxoSmithKline, Intarcia, Janssen, MedImmune, Merck, Novartis, Pfizer, Poxel, Quark Pharmaceuticals, Roche, Takeda, The Medicines Company, Zora Biosciences. A.N.M., R.C., J.V., M.T. and F.N. have nothing to disclose. |
| Conflict of interest: J.C.N. reports receipt of grants/research support from Astrazeneca, Bayer, Bristol-Myers Squibb, CLS Behring, Dalcor, Janssen, Novartis, NovoNordisk, Sanofi, Vifor; receipt of honoraria or consultation fees from Amgen, Bayer, Novartis, Sanofi, Servier: participation in a company sponsored speaker’s bureau Daiichi-Sankyo, Servier. C.T.R. received research grant through institution: Boehringer Ingelheim, Daiichi Sankyo, MedImmune, National Institutes of Health; Honoraria for scientific advisory boards and consulting: Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Janssen, MedImmune, Pfizer, Portola, Anthos. W.Z. and M.K. are employees of Daiichi Sankyo. T.D. and S.J-M. received research grant support from Daiichi Sankyo. E.M.A. received research grant from Daiichi-Sankyo to Brigham and Women’s Hospital for clinical trial with edoxaban. R.P.G. reports Clinical trials/ Research support: Amgen, Daiichi Sankyo. Honoraria for CME Lectures: Amgen, Daiichi Sankyo, Servier. Consultant: Akcea, Amarin, Amgen, Bristol-Myers-Squibb, CVS Caremark, Daiichi Sankyo, Janssen, Lexicon, Pfizer. The TIMI Study Group has received institutional research grant support through Brigham and Women’s Hospital from: Abbott, Amgen, Aralez, AstraZeneca, Bayer HealthCare Pharmaceuticals, Inc., Daiichi-Sankyo, Eisai, GlaxoSmithKline, Intarcia, Janssen, MedImmune, Merck, Novartis, Pfizer, Poxel, Quark Pharmaceuticals, Roche, Takeda, The Medicines Company, Zora Biosciences. A.N.M., R.C., J.V., M.T. and F.N. have nothing to disclose. |
